Why JPMorgan thinks recession fears aren't to blame for the stock market's pain — and why the worst of the sell-off may be over
Stocks have plunged in amid fears that tariffs will weigh on economic growth. Yet, there may be a more under-the-radar reason ...
Morningstar3d
Sarepta's stock slammed after patient dies of liver failure. Here's what Wall Street is saying.
making it one of the most expensive therapies in the U.S. Mizuho said the selling of the stock was likely an overreaction, noting that this is the first case of acute liver failure among patients ...
Trump shrugs off stock market slump, but economic warning signs loom
During Donald Trump’s first term as US president, he regularly referred to rising stock markets as evidence of the success of ...
The Upside-Down Line That Tells the Story of the Stock Market Now
When President Trump entered his first term, stocks were steadily marching upward. This time, the trajectory has inverted.
Yahoo Finance2d
Stock market today: Nasdaq leads stocks lower as Nvidia falls with GTC event underway
In a statement, Sarepta said the patient died of acute liver failure, a known side ... potential near-term hurdles." Nvidia stock (NVDA) fell 3% at the market open on Tuesday ahead of the AI ...
Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Morningstar3d
Sarepta Therapeutics stock falls after DMM patient dies of liver failure
Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug ...
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.